Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N9D9 | ISIN: US60770K1079 | Ticker-Symbol: 0QF
Tradegate
10.02.26 | 21:54
35,115 Euro
-0,31 % -0,110
1-Jahres-Chart
MODERNA INC Chart 1 Jahr
5-Tage-Chart
MODERNA INC 5-Tage-Chart
RealtimeGeldBriefZeit
35,24035,38010.02.
35,12535,48010.02.
ACCESS Newswire
464 Leser
Artikel bewerten:
(2)

Moderna, Inc.: Moderna Named a Top Employer by Science for Eleventh Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees.

"We are honored to be recognized by Science as a top employer, with this year marking the eleventh consecutive year we have been named to this important list," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our team continues to execute our strategy, advancing our pipeline of mRNA medicines and staying focused on our commitment to patients. I am proud that Moderna remains a company where our team members can build purposeful careers."

In 2025, Moderna received approval for its third product, mNEXSPIKE®, a new vaccine against COVID-19 for use in all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factors. As its product portfolio grows, Moderna has continued to invest in its global network of advanced manufacturing hubs in Australia, Canada and the United Kingdom, which strengthen pandemic readiness by maximizing geographic coverage and minimizing response times. As part of Moderna's ongoing commitment to social responsibility, the Company also marked the third anniversary of the Moderna Charitable Foundation and issued its fourth annual Impacting Human Health Report.

"At Moderna, we are bringing together people and technology to change what's possible in medicine," said Tracey Franklin, Chief People and Digital Technology Officer of Moderna. "Our teams are constantly adapting, learning and applying new tools, like AI and robotics, in ways to drive innovation and create meaningful impact for years to come."

For more than 20 years, Science has surveyed its readership to identify and celebrate the top 20 pharmaceutical and biotechnology companies with the best reputation as employers. The 2025 survey's findings are based on approximately 5,500 completed surveys from readers of Science, and other survey invitees. A vast majority of the survey participants came from North America (66%), Europe (20%) and Asia/Pacific Rim (9%). Most (97%) of the respondents worked in biotechnology, biopharmaceutical and pharmaceutical companies.

For the complete feature along with individual company rankings, please visit: https://www.science.org/content/article/2025-s-top-employers-innovation-ai-and-policy-biotech-pharma

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna Contacts

Media:
Chris Ridley
Head, Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-named-a-top-employer-by-science-for-eleventh-consecutive-year-1091309

© 2025 ACCESS Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.